Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00108173 · ClinicalTrials.gov registry record · Phase 1

Brain Reaction to Treatment of Nicotine Dependence

A Phase 1 study of Nicotine Dependence, sponsored by US Department of Veterans Affairs.

Completed
Registry status
Phase 1
Development phase
104
Enrollment target
1
Study location

NCT00108173 is a Phase 1 study of Nicotine Dependence that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 104 participants, below the 185-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00108173, a Phase 1 study of Nicotine Dependence, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
Phase 1
Development phase
104 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study was to determine how the treatments for cigarette craving work. Hypothesis: During exposure to cigarette-related cues, heavy smokers will have greater reductions in regional brain activation from before to after both forms of active treatments than from before to after placebo.

Conditions Studied

Interventions

  • DRUG Zyban

Study Locations (1)

California

  • VA Greater Los Angeles Healthcare System, West LA - West Los Angeles

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2002-10
Est. Completion 2011-06
Phase Phase 1

Sponsor

US Department of Veterans Affairs

632 total trials

What the Registry Record Tells You About NCT00108173

The ClinicalTrials.gov registry entry for NCT00108173 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 185-participant average among 67 other Nicotine Dependence trials with a reported enrollment target (44% lower). The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Nicotine Dependence appearing as the primary indexed condition, and to 1 intervention - of which Zyban is the first listed.

NCT00108173 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00108173 about?

NCT00108173 is a clinical study titled "Brain Reaction to Treatment of Nicotine Dependence". The purpose of the study was to determine how the treatments for cigarette craving work. Hypothesis: During exposure to cigarette-related cues, heavy smokers will have greater reductions in regional brain activation from before to after both forms of active treatments than from before to after plac...

What is the current status of trial NCT00108173?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2002-10. Estimated completion is 2011-06.

What conditions does trial NCT00108173 study?

This clinical trial studies the following conditions: Nicotine Dependence.

What interventions are being tested in trial NCT00108173?

The interventions under investigation include: Zyban (DRUG).

Who is sponsoring clinical trial NCT00108173?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00108173 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nicotine Dependence

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.